Pharmagenix   Report issue

For profit Phase 2 Phase 3
Founded: Zurich Switzerland (2009)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2016
NCT02735070
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

chlorpheniramine (ChlorTrimeton) (1 trial)

Drugs in Phase 2 Trials (3)

folic acid (1 trial)

gerilimzumab (1 trial)

naltrexone (revia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Common Cold (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5